Monoclonal gammopathy of uncertain significance

This early-stage trial tests whether specially trained immune cells can safely target and attack multiple myeloma, as well as its early forms MGUS and smoldering myeloma. Up to 36 participants will receive two infusions of their own T cells that have been engineered to recognize …

This phase 2 trial tests whether the drug zanubrutinib, combined with standard rituximab, can improve nerve damage and disability in people with a rare blood condition called IgM MGUS. The study includes 35 adults across two Dutch hospitals. Participants take zanubrutinib daily f…

This phase 2 trial is testing the drug daratumumab in 42 people with high-risk MGUS or low-risk smoldering multiple myeloma—early, pre-cancerous conditions that can lead to multiple myeloma. The goal is to see if daratumumab can produce a deep response (very good partial response…

This study tests whether combining acalabrutinib with rituximab is safe and effective for people with nerve damage (neuropathy) linked to two blood conditions: IgM MGUS or Waldenstrom macroglobulinemia. The main goal is to see if the treatment lowers a key protein (IgM) in the bl…

This study aimed to test if daratumumab could improve nerve damage (peripheral neuropathy) in people with a blood condition called MGUS. Participants would have received weekly injections for two months, then biweekly for four more months. However, the trial was withdrawn before …

This study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Tho…

This phase 2 trial is testing whether metformin, a widely used diabetes medication, can prevent progression to multiple myeloma in 60 people with early blood disorders called MGUS and smoldering multiple myeloma. Participants receive either extended-release metformin or a placebo…

This study tests whether a plant-based diet is practical for overweight people with MGUS or smoldering multiple myeloma, conditions that can lead to multiple myeloma. For 12 weeks, 23 participants receive two pre-made plant-based meals daily. Researchers track weight loss and die…

This study screens 1000 adults aged 40 and older for MGUS, a condition with an abnormal blood protein that can sometimes lead to multiple myeloma. Researchers want to learn about genetic and immune factors behind MGUS, especially in diverse populations. The goal is to improve ear…

The PROMISE study is enrolling 30,000 people at high risk for multiple myeloma, including African Americans and those with a family history of blood cancers. Participants provide blood samples so researchers can track changes over time and identify who progresses to myeloma. The …

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for future research to understand what causes these cancers, how they pr…

This study tests a new lab method to see how certain bone marrow cells take up nutrients like glucose and amino acids. Researchers will compare cells from people with a pre-cancer condition called MGUS to cells from healthy volunteers. The goal is to better understand the disease…

This study is screening over 80,000 people in Iceland to see if early detection of a condition called MGUS can prevent or improve outcomes for multiple myeloma, a type of blood cancer. Participants are randomly assigned to routine care or closer monitoring. The goal is to compare…